Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
The positive stance follows the nomination of EDIT-401 as the company's lead Vivo program. Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program Photo by Myriam Zilles on Unsplash The company is developing EDIT-401 as a one-time therapy for reducing LDL cholesterol levels. The company is developing the program as an experimental, transformative in vivo gene editing medicine based on an upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. Its nomination as a lead in vivo development candidate marks a significant milestone in Edita's long-term vision to lead the field of in vivo programmable gene editing. “At Editas Medicine, we believe in vivo is the future of medicine. With EDIT-401, we're advancing our differentiated upregulation strategy to develop a next-generation medicine that can deliver lasting impact for patients,” said Gilmore O'Neill, Chief Exec
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Chardan Capital from a "hold" rating to a "strong-buy" rating.MarketBeat
- Editas Medicine Announces Third Quarter 2025 Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Editas Medicine Announces Third Quarter 2025 Results and Business UpdatesGlobeNewswire
- Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025GlobeNewswire
- Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
EDIT
Earnings
- 11/10/25 - Beat
EDIT
Analyst Actions
- 11/15/25 - Chardan Capital
EDIT
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- EDIT's page on the SEC website